<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990805</url>
  </required_header>
  <id_info>
    <org_study_id>BSR-CTph3-JS1</org_study_id>
    <nct_id>NCT03990805</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis</brief_title>
  <official_title>Multi-center, Randomized, Double-Blind, Placebo Controlled Phase 3 Clinical Trial to Evaluate Efficacy and Safty of Mesenchymal Stem Cells JointStem in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R-Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of autologous Adipose&#xD;
      Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee&#xD;
      Osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JOINTSTEM is injectables for an OA treatment that uses autologous adipose-derived mesenchymal&#xD;
      stem cells. As it does not use allogenic tissues and is cultured without additional genetic&#xD;
      modification, it is classified as 'autologous cell therapy' and is completely free of&#xD;
      immunologic rejection.&#xD;
&#xD;
      It primarily aims to improve joint function. The intra-articular injection of JOINTSTEM is&#xD;
      expected to stimulate the regeneration of cartilage, and to innovatively improve joint&#xD;
      function with cartilage regeneration.&#xD;
&#xD;
      The subjects of this therapy were patients with K&amp;L grade 3 aged 20 or older.&#xD;
&#xD;
      This study is a double-blind, randomized, placebo controlled study with two arms to evaluate&#xD;
      JOINTSTEM as a treatment for subjects with osteoarthritis. Following a 2-week screening&#xD;
      period, approximately 260 patients will be randomly assigned into one of the following two&#xD;
      arms in a 1:1 ratio (1 JointStem : 1 placebo control). After each patient completes 6-month&#xD;
      visit (Visit 5) and the data management team confirms all data have no issue, the individual&#xD;
      database will be locked and the blinding will be open for the statistical analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Pain, stiffness, and physical function of the knee will be measured by the WOMAC score&#xD;
Score range is&#xD;
0-20 for Pain&#xD;
0-8 for Stiffness&#xD;
0-68 for Pysical Function&#xD;
Higher scores on the WOMAC indicate wors pain, stiffness, and functional limitations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Visual Analog Scale (VAS) scores from baseline</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Pain of knee will be measured by the 100mm VAS&#xD;
-Score range is from 0-4mm(no pain) to 75-100mm(severe pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC 3 subscale score</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Pain of knee will be measured by the 100mm Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS)&#xD;
-Score range is from 0(extreme symptoms) to 100(no symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>The SF(Short Form)-36 Health Survey is a 36-item, patient-reported survey of patient health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC</measure>
    <time_frame>12weeks, 24 weeks</time_frame>
    <description>Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring of Kellgren-Lawrence grade</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Measuring of Kellgren-Lawrence grade through X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring of Femoro-tibial anatomical angle(FTA)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Measuring of FTA through X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring of Hip-Knee-Ankle angle(HKA)</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Measureing of HKA through X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring of Joint Space Width</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>measuring Joint Space Width through X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI scan</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>MRI perform to measure Modified WORMS (Whole-Organ Magnetic Resonance Imaging Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
    <description>Frequency and total amount of rescue medication administration will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Degenerative Arthritis</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>JOINTSTEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Adipose Tissue derived MSCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JOINTSTEM</intervention_name>
    <description>JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection</description>
    <arm_group_label>JOINTSTEM</arm_group_label>
    <other_name>Autologous Adipose Tissue derived MSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>saline, 1 time injection</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 20 and older, male and female&#xD;
&#xD;
          2. Patients must consent in writing to participate in the study by signing and dating an&#xD;
             informed consent document&#xD;
&#xD;
          3. Diagnosis of degenerative arthritis of class 1-3 by ACR(American College of&#xD;
             Rheumatology Criteria) Global functional criteria&#xD;
&#xD;
          4. Diagnosis of Kellgren and Lawrence grade 3 by radiographic criteria&#xD;
&#xD;
          5. Patients suitable for one of three conditions of 'diagnostic criteria for&#xD;
             osteoarthritis of knee' based on ACR guideline&#xD;
&#xD;
               -  clinical and inspectional opinion&#xD;
&#xD;
               -  clinical and radiographic opinion&#xD;
&#xD;
               -  clinical opinion&#xD;
&#xD;
          6. Patients who has joint pain ≥ 50mm on 100mm VAS (Visual Analog Scale) at Screening&#xD;
&#xD;
          7. Patient who has WOMAC score ≥ 1000 at Screening&#xD;
&#xD;
          8. No improvement with persisting knee pain at least for 12 weeks (3 months) by&#xD;
             nonoperational therapy before Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have pregnancy plans within this trial period or childbearing age&#xD;
             patients who do not agree to maintain contraception status through appropriate&#xD;
             contraception methods&#xD;
&#xD;
               -  Appropriate contraception method: Use of condom, contraceptive sponges, foam,&#xD;
                  diaphragm, intrauterine device etc.&#xD;
&#xD;
               -  Periodic abstinence(e.g. methods of predicting ovulation) and moderation are not&#xD;
                  considered as appropriate contraception method.&#xD;
&#xD;
               -  Not allowed to use hormonal contraceptives&#xD;
&#xD;
               -  Childbearing age female patients, exclude menopausal female (amenorrhea for more&#xD;
                  than 24 months after the last menstruation) or female who has no possibility of&#xD;
                  pregnency by surgical sterilization operation, can participate in this study only&#xD;
                  determined negative in pregnancy test&#xD;
&#xD;
          2. Pregnant women or lactating mothers&#xD;
&#xD;
          3. Patients with Body Mass Index (BMI) &gt; 35&#xD;
&#xD;
          4. Patients with positive human immunodeficiency (HIV), hepatitis B (HBV), hepatitis C&#xD;
             (HCV), syphilis at screening indicative of current of pass infection&#xD;
&#xD;
          5. Patients with other disease including&#xD;
&#xD;
               -  Septic arthritis, Rheumatoid or Inflammatory joint disease, Gout, Reccurent&#xD;
                  pseudogout, Paget disease, Articular fractures, Ochronosis, Acromegaly,&#xD;
                  Hemochromatosis, Wilson's disease,Osteochondromatosis, Hereditary disorder,&#xD;
                  Genetic disorder of collagen&#xD;
&#xD;
          6. Patients who are diagnosed with malignant tumor in the past or present&#xD;
&#xD;
          7. Patients who have clinically significant diseases including&#xD;
&#xD;
               -  Cardiac disorder (Myocardial infarction, Coronary artery bypass graft, Arrhythmia&#xD;
                  and other severe Cardiac disorder etc.)&#xD;
&#xD;
               -  Resistant hypertension (systolic blood pressure &gt; 160mmHg or diastolic pressure &gt;&#xD;
                  100mmHg at Screening)&#xD;
&#xD;
               -  Kidney disease (Chronic renal failure, Glomerulonephritis etc.)&#xD;
&#xD;
               -  Liver disease (Hepatocirrhosis, Fatty liver, acute or chronic liver disease etc.)&#xD;
&#xD;
               -  Endocrinopathy (Thyroiditis, Diabetes insipidus, Cushing disease etc.)&#xD;
&#xD;
          8. Patients who have significant lab abnormalities&#xD;
&#xD;
          9. Patients who have severe pain in other areas that can affect the judgement of knee&#xD;
             joint symptom&#xD;
&#xD;
         10. Patients who underwent any arthroscopic surgery on the injection site within 6 months&#xD;
             of the screening visit date, or scheduled to perform any surgery during the clinical&#xD;
             trial period&#xD;
&#xD;
         11. Patients who received any drug by intra-articular injection(hyaluronic acid or steroid&#xD;
             etc.) for treatment within 6 months prior to Screening&#xD;
&#xD;
         12. Patients who experienced as stem cell therapy or blood product injection(PRP, Prolo&#xD;
             injection etc.)&#xD;
&#xD;
         13. Patients who received treatment within 14 days prior to Screening including(But,&#xD;
             patients who had wash-out-period can participate in this study)&#xD;
&#xD;
               -  Take medicines including composition of Glucosamine, Chondretin sulphate and&#xD;
                  Diacerhein etc.&#xD;
&#xD;
               -  Take phytotherapeutic agent or Chinese medicine for osteoarthritis&#xD;
&#xD;
               -  Take antiinflammatory analgesic drug, NSAIDs (prescription/nonprescription&#xD;
                  pharmaceuticals) etc. (Patients who have 3 days of wash-out-period after they&#xD;
                  took acetaminophen can participate in the study)&#xD;
&#xD;
               -  Take oral steroids&#xD;
&#xD;
               -  Physical therapy or Chinese medical treatment(cupping, acupuncture, moxibustion&#xD;
                  etc.)&#xD;
&#xD;
         14. Patients with penicillin hypersensitivity reactions&#xD;
&#xD;
         15. Patients with skin diseases or infections in the area of the injection site&#xD;
&#xD;
         16. Patients who have abnormal flail over grade 2 flail knee test of anterior to posterior&#xD;
             and varus/valgus lesion at physical examination&#xD;
&#xD;
         17. Patients who have difficulty in taking MRI because of metal materials (cardiac&#xD;
             pacemaker or clip of cerebral artery etc.) in their body or claustrophobia -but,&#xD;
             patients with metal materials that are not affected by magnetic field can participate&#xD;
             in this study&#xD;
&#xD;
         18. Patients who have difficulty in liposuction or local anesthesia&#xD;
&#xD;
         19. Patients who have alcohol, drug abuse history&#xD;
&#xD;
         20. Patients who have severe neurologic and psychiatric disorders that affect clinical&#xD;
             trials&#xD;
&#xD;
         21. Patients who had participated in other clinical trials within 12 weeks prior to this&#xD;
             study&#xD;
&#xD;
         22. Patients who the principal investigator considers inappropriate for the clinical trial&#xD;
             due to any other reasons than those listed above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KANGIL KIM</last_name>
    <role>Principal Investigator</role>
    <affiliation>KyungHee University Gangdong Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>WOOSUK LEE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SUNCHUL HWANG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SANGJUN SONG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KICHEOR BAE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>YOUNGWAN MOON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JUHONG LEE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HANJUN LEE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chunang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EUISUNG CHOI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HYUNGSUK CHOI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital Seoul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KWANKYU PARK</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>OOGJIN SHON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju-si</city>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Gangdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chunang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cell</keyword>
  <keyword>Adipose tissue derived mesenchymal stem cell</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>degenerative arthritis</keyword>
  <keyword>biostar</keyword>
  <keyword>Rbio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

